Involving Peptidase Patents (Class 435/24)
-
Patent number: 8697386Abstract: The invention provides methods and compositions for modulating hepsin activity and the MSP/Ron pathway, in particular by regulating pro-MSP activation by hepsin.Type: GrantFiled: October 21, 2010Date of Patent: April 15, 2014Assignee: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Patent number: 8685392Abstract: The invention relates to glutamine endopeptidase enzymes from Rothia spp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.Type: GrantFiled: October 7, 2010Date of Patent: April 1, 2014Assignee: Trustees of Boston UniversityInventors: Eva J. Helmerhorst, Frank G. Oppenheim
-
Patent number: 8673557Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.Type: GrantFiled: February 24, 2012Date of Patent: March 18, 2014Assignee: Seattle Children's Research InstituteInventors: Andrew M. Scharenberg, Michael T. Certo, Kamila S. Gwiazda
-
Publication number: 20140072960Abstract: A test unit collects and analyzes biological specimens on-site. It has one or more openings that allow reagent capsules to be inserted and guided into a testing chamber. Reagent capsules are preloaded with chemicals for screening and are configured as blister packs. A button mechanism allows projection(s) to open the blister packs to allow chemicals within the capsules to mix inside the testing chamber. A medical swab is affixed to a pop top dispenser cap and can be pressed to allow the swab to be inserted into the mixed chemicals. A visible test strip mount attached to the testing chamber has a lever to manipulate a test strip in and out of the testing chamber. This test strip may be slid through a uni-directional seal on a capsule and into a chemical for testing. The test strip will test for the presence of an infectious disease.Type: ApplicationFiled: May 31, 2013Publication date: March 13, 2014Inventor: Bliss Hanlon Lansing
-
Publication number: 20140072992Abstract: Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed.Type: ApplicationFiled: August 26, 2013Publication date: March 13, 2014Applicants: Progenra, Inc., Lifesensors, Inc.Inventors: Dattananda Chelur, Michael Eddins, Craig Leach, Steven J. Orcutt, Raymond J. Peroutka, James Strickler, Yilin Yan, Kathryn Longenecker
-
Patent number: 8669116Abstract: The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes.Type: GrantFiled: March 11, 2003Date of Patent: March 11, 2014Assignee: President and Fellows of Harvard CollegeInventors: Steven P. Gygi, Junmin Peng
-
Publication number: 20140065652Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.Type: ApplicationFiled: September 5, 2013Publication date: March 6, 2014Applicant: Momenta Pharmaceuticals, Inc.Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
-
Publication number: 20140045205Abstract: The present invention relates to a method and a kit for the diagnosis and/or prognosis of kidney injury comprising analysing a sample obtained from a patient and determining the activity of at least one aminopeptidase selected from aspartyl aminopeptidase, glutamyl aminopeptidase, alanyl aminopeptidase and leucyl-cystinyl aminopeptidase.Type: ApplicationFiled: November 10, 2011Publication date: February 13, 2014Applicants: UNIVERSIDAD DE GRANADA, SERVICIO ANDALUZ DE SALUD, UNIVERSIDAD DE JAENInventors: Antonio Osuna Ortega, Rosmary Wangensteen Fuentes, José Félix Vargas Palomares, Manuel Ramirez Sanchez
-
Patent number: 8642356Abstract: The present invention relates to a cascade enzyme-linked immunosorbent assay, more precisely a cascade enzyme-linked immunosorbent assay using magnetic microparticles (MMPs) immobilized with the target antigen specific primary antibody and silica nanoparticles (SPs) immobilized with a cascade reaction initiator and the antigen-specific secondary antibody. When the method of the present invention is applied in the detection of an antigen in biosamples, the detection sensitivity can be significantly increased.Type: GrantFiled: May 30, 2008Date of Patent: February 4, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Sang Jeon Chung, Young-mi Lee, Yu-Jin Jeong, Hyo Jin Kang, Bong Hyun Chung
-
Publication number: 20140011815Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.Type: ApplicationFiled: July 2, 2013Publication date: January 9, 2014Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun E. Ghosh
-
Publication number: 20140011191Abstract: The present invention relates to devices and methods for measuring the quantity of multiple analytes in a sample. The device is designed such that each of the analyte sensing elements is configured to measure the quantity of a predetermined analyte and where the machine executable instructions are configured to select the proper analyte sensing element corresponding to the analyte to be measured.Type: ApplicationFiled: September 4, 2013Publication date: January 9, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Matthew Beaudet, Jill Hendrickson, David Hagen, Rich Meyer
-
Publication number: 20140004531Abstract: The instant invention relates to the field of protein production, and in particular is relates to compositions and processes for improving the production levels of recombinant proteins expressed in host cells.Type: ApplicationFiled: August 30, 2013Publication date: January 2, 2014Applicant: ABBVIE INC.Inventors: Patrick Hossler, Ivan Correia
-
Publication number: 20130344525Abstract: Provided herein are methods for quantitating glutamate carboxypeptidase II activity in a biological sample, such as a skin biopsy sample, and for determining whether an agent is inhibiting GCP in a subject.Type: ApplicationFiled: January 5, 2012Publication date: December 26, 2013Applicant: 6The Hohns Hopkins UniversityInventors: Barbara S. Slusher, Michael Polydefkis, Camilo Rojas, Marigo Stathis
-
Publication number: 20130344197Abstract: The present invention relates to novel broad spectrum strains of baker's yeast, i.e. yeast strains that are effective on both dough known as unsweetened dough and dough known as sweet dough.Type: ApplicationFiled: June 20, 2013Publication date: December 26, 2013Inventors: Jean-Charles Bartolucci, Didier Colavizza, Melanie Legros, Georges Pignede
-
Patent number: 8613918Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.Type: GrantFiled: May 25, 2012Date of Patent: December 24, 2013Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20130337480Abstract: The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.Type: ApplicationFiled: December 14, 2011Publication date: December 19, 2013Applicants: CHIRALIX B.V., STICHTING KATHOLIEKE UNIVERSITEITInventors: Waander Laurens Van Heerde, Richard Hendrik Blaauw
-
Publication number: 20130330758Abstract: At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.Type: ApplicationFiled: February 20, 2012Publication date: December 12, 2013Applicant: KOREA FOOD RESEARCH INSTITUTEInventors: Nam-Soo Kim, Chong-Tai Kim, Yong-Jin Cho, Chul-Jin Kim, Jin-Soo Maeng, Soo-Jin Kwon
-
Patent number: 8592142Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.Type: GrantFiled: December 10, 2012Date of Patent: November 26, 2013Assignee: Momenta Pharmaceuticals, Inc.Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
-
Patent number: 8592174Abstract: The present invention relates to the use of a compound of the following formula (I), as an enzyme substrate for the detection of a peptidase activity or as a pH indicator: according to which: Y1 is a peptide, H or an alkyl; W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination thereof; n=0, 1 or 2; U is N or N+R and V is CZ6N or N+R or else V is N or N+R and U is CZ6; R is H, alkyl, aralkyl, aryl, alkanoyl or alkylsulfonyl; Z1, Z2, Z3, Z4 and Z5 are independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulfonyl, including the carboxyl or sulfonyl esters or amides, and salts thereof.Type: GrantFiled: July 28, 2010Date of Patent: November 26, 2013Assignee: bioMérieux, S.A.Inventors: Olivier Fabrega, Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Patent number: 8586325Abstract: Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.Type: GrantFiled: May 10, 2013Date of Patent: November 19, 2013Assignee: Biotium, Inc.Inventors: Fei Mao, Hui Cen
-
Patent number: 8584892Abstract: A packet of an enzyme and/or enzyme producing bacteria is contained within the core of a roll of toilet tissue or similar paper product wound on a core. The packet has a cover that dissolves or disintegrates on contact with water and disperses its contents into the aqueous waste stream. The packet may contain a mixture of bacterial cultures that produce enzymes to attack the greasy or fatty components of the waste stream. An additional article such as a sample of a liquid or creme personal care product may also be contained within the tissue paper core.Type: GrantFiled: January 19, 2010Date of Patent: November 19, 2013Inventor: Joseph R. Lira
-
Patent number: 8580534Abstract: A method for comparative proteomics using a peptidase under enzymatic conditions that permits the optimal incorporation of two oxygen atoms into a digested peptide. The method employs a peptidase to incorporate two 18O atoms into a peptide set derived from a population of proteins at a conditioned state, which is compared to a second peptide set incorporated with a single 16O atom derived from a population of proteins at a second conditioned state. Upon combining the two peptide sets, the populations of proteins are analyzed for qualitative and quantitative differences based on the content of 18O atoms and 16O atoms in the digested peptides using mass spectrometry instrumentation. The method is advantageous to improve the efficiency and timeframe of peptidase catalyzed 18O labeling reactions which increased the accuracy and reliability of quantitative proteomic experiments.Type: GrantFiled: July 2, 2007Date of Patent: November 12, 2013Assignee: The University of North DakotaInventor: Masaru Miyagi
-
Patent number: 8568716Abstract: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.Type: GrantFiled: June 16, 2006Date of Patent: October 29, 2013Assignee: Proteon Therapeutics, Inc.Inventor: F. Nicholas Franano
-
Patent number: 8562983Abstract: The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.Type: GrantFiled: August 22, 2008Date of Patent: October 22, 2013Assignee: Proteon Therapeutics, Inc.Inventor: F. Nicholas Franano
-
Publication number: 20130273027Abstract: Mutant enzymes and methods of use thereof are provided.Type: ApplicationFiled: March 13, 2013Publication date: October 17, 2013Inventors: Craig Leach, Michael Eddins, David Stemer, Benjamin Nicholson
-
Patent number: 8557536Abstract: An object of the present invention is to provide a detection method capable of detecting articular cartilage degeneration or damage in which the abnormality cannot be detected in a radiograph in a simple method and with high accuracy, a method of evaluating the rate of progression of articular cartilage degeneration or damage, and the like. The present invention as a means for achieving the object provides a method of detecting articular cartilage degeneration or damage which cannot be detected in a radiograph, by using the concentration of keratan sulfate in a sample derived from blood as an index, and the like. Further, the present invention provides a method of evaluating the rate of progression of articular cartilage degeneration or damage by using the concentration of keratan sulfate in a sample derived from blood as an index, and the like.Type: GrantFiled: February 5, 2008Date of Patent: October 15, 2013Assignee: Seikagaku CorporationInventors: Shigeyuki Wakitani, Masashi Nawata, Kyosuke Miyazaki, Hiroyuki Masuda, Hiroshi Fujita, Yasuhiro Kurahashi
-
Publication number: 20130266977Abstract: Provided herein are methods, test units, systems, assays and kits for qualitative and/or quantitative detection of microorganisms or microbes. Some aspects of the invention utilize a test strip comprising a test area and a self-calibrating control area that permits quantitative measurements to be obtained rapidly at the test site. The test strip is ready-to-use and does not require any preparation. The present systems and methods provide valuable tools for sensitive early detection of microbial contamination.Type: ApplicationFiled: February 16, 2011Publication date: October 10, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Ralph Mitchell, Nick Konkol, Christopher J. McNamara, Marc Mittelman, Michael Laine
-
Patent number: 8551727Abstract: Disclosed are a metal nanoparticle onto which a peptide substrate specifically degraded by protease and fluorophore are chemically modified for selectively imaging protease expressed in cell and in tissue in a human body, and the use thereof. Also, a quantitative analysis method of protease using the metal nanoparticle, a cell imaging method and a drug screening method of inhibiting a protease overexpression are provided. In detail, the present invention is directed to a metal nanoparticle having a peptide substrate and fluorophore coupled thereto, the peptide substrate and the fluorophore being specifically degraded by due to a protease activated in various ways in cell and in a human body to exhibit fluorescence. Hence, the metal nanoparticle can be used to rapidly screen activation and inhibition of the protease in the imaging manner.Type: GrantFiled: April 10, 2008Date of Patent: October 8, 2013Assignee: Korea Institute of Science and TechnologyInventors: Ick-Chan Kwon, Kui-Won Choi, Kwang-Meyung Kim, Cheol-Hee Ahn, In-Chan Youn, Seul-Ki Lee, Kyeong-Soon Park
-
Publication number: 20130251640Abstract: Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer.Type: ApplicationFiled: December 1, 2011Publication date: September 26, 2013Applicant: THE METHODIST HOSPITAL SYSTEMInventors: Ching-Hsuan Tung, Wael R. Abd-Elgaliel
-
Publication number: 20130244954Abstract: The invention is in the field of biotechnology. Specifically it describes the application and pharmaceutical composition of Reg4. The invention describes the applications of the protein as following in (a) or (b) in preparing drugs for treating acute pancreatitis: (a) the protein whose amino acid sequence is shown as SEQ ID NO. 1, or bioactive fragments, or analogs; (b) the proteins whose amino acid sequence have at least 70% homology comparing with amino acid sequence described in (a) and have activity for treating acute pancreatitis. The protein described in this invention treats acute pancreatitis effectively and may provide new therapy for treating acute pancreatitis clinically.Type: ApplicationFiled: August 8, 2011Publication date: September 19, 2013Applicant: SHANGHAI REGENOME BIOMEDICAL TECHNOLOGY CO., LTD.Inventors: Wei Han, Yan Yu, Guoyong Hu
-
Patent number: 8535901Abstract: The present invention relates to the use of a compound of the following formula (I) for detecting a peptidase activity and/or a variation in pH: according to which: Y1 is a peptide, H or an alkyl; W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination thereof; n=0, 1 or 2; U and V are N, N+R or CZ4, R being H, alkyl, aralkyl, aryl, alkanoyl or alkylsulfonyl; Z1, Z2, Z3 and Z4 being independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulfonyl, including the carboxyl or sulfonyl esters or amides, and salts thereof.Type: GrantFiled: July 28, 2010Date of Patent: September 17, 2013Assignee: bioMérieux, S.A.Inventors: Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Patent number: 8535902Abstract: The present invention relates to the use of a compound of the following formula (I) for detecting a peptidase activity and/or a variation in pH: according to which: Y1 is a peptide, H or an alkyl; W1, W2, W3 and W4 are independently H, Br, Cl, F, I, alkyl, alkoxy, thiomethyl, perfluoroalkyl, nitro, cyano, carboxyl (including the esters or amides thereof) or any combination thereof; n=0, 1 or 2; X is NR, CZ5Z6, S or O, R being H, alkyl, aralkyl, aryl, alkanoyl or alkylsulfonyl, Z5 and Z6 being an alkyl; Y is N or N+R, R being alkyl, aralkyl, aryl, alkanoyl or alkylsulfonyl; Z1, Z2, Z3 and Z4 being independently H, Br, Cl, F, I, alkyl, aryl, alkoxy, perfluoroalkyl, nitro, cyano, carboxyl, sulfonyl, including the carboxyl or sulfonyl esters or amides, and salts thereof.Type: GrantFiled: July 27, 2010Date of Patent: September 17, 2013Assignee: bioMërieux, S.A.Inventors: Olivier Fabrega, Arthur James, Sylvain Orenga, John Perry, Vindhya Salwatura, Stephen Stanforth
-
Patent number: 8497127Abstract: The invention provides a synthetic phytase polypeptide which encodes an enzymatically susceptible phytase. Also provided are feed or food products comprising an enzymatically susceptible phytase, and transgenic plants which express the enzymatically susceptible phytase. Further provided are methods for making and using enzymatically susceptible phytases, e.g., a method of using an enzymatically susceptible phytase in feed and food processing.Type: GrantFiled: November 21, 2008Date of Patent: July 30, 2013Assignee: Syngenta Participations AGInventors: Shib Sankar Basu, Shengsheng Zhang
-
Patent number: 8497086Abstract: A reaction medium for detecting and/or identifying methicillin-resistant Staphylococcus aureus (MRSA) bacteria includes a chromogenic substrate, a first antibiotic that belongs to the cephalosporin family and a second antibiotic that belongs to the aminoglycoside family.Type: GrantFiled: July 20, 2010Date of Patent: July 30, 2013Assignee: BiomereuxInventors: Jean-Marc Roche, Gilles Zambardi
-
Patent number: 8492109Abstract: The present invention relates to methods, systems, and kits for intoxicating cells, neuronal and non-neuronal cells, with a toxin or fragment thereof. This is done by subjecting toxin substrate and a lipid or polymeric carrier (e.g., DNA uptake facilitating agent) to one or more cells for use in cell based assays. In an aspect, the methods of the present invention allow for high throughput assays and, as such, for the evaluation of drug candidates.Type: GrantFiled: January 20, 2010Date of Patent: July 23, 2013Assignee: Trustees of Tufts CollegeInventors: George A. Oyler, Charles B. Shoemaker, Chuehling Kuo
-
Publication number: 20130184173Abstract: Biomarkers that can be used for the diagnosis and prognosis of multiple sclerosis in pediatric patients presenting with clinically isolated syndrome or acquired demyelination syndrome are described.Type: ApplicationFiled: April 14, 2011Publication date: July 18, 2013Applicant: The Royal Institution for the Advancement of Learning/Mcgill UniversityInventors: Amit Bar-Or, Elizabeth Colman, Katja Geling
-
Patent number: 8460862Abstract: The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues.Type: GrantFiled: March 11, 2009Date of Patent: June 11, 2013Assignee: Marker Gene TechnologiesInventors: Daniel J. Coleman, John J. Naleway
-
Publication number: 20130143251Abstract: The present invention discloses a process for preparing ubiquinated peptide conjugates comprising a ubiquitin peptide residue UR attached at its C-terminus to a substrate peptide via a native isopeptide bond, this process comprising combining Native Chemical Ligation (NCL) and solid phase peptide synthesis (SPPS). Further are disclosed ubiquinated peptide conjugates containing a native isopeptide bond, as well as various uses thereof.Type: ApplicationFiled: June 1, 2011Publication date: June 6, 2013Applicant: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITYInventors: Ashraf Brik, Ajish Kumar, Leslie Erlich, Liat Spasser
-
Patent number: 8455185Abstract: A diagnostic test kit for detecting the presence or quantity of an enzyme or enzyme inhibitor is provided. The diagnostic kit utilizes reactive complexes to facilitate the detection of the enzyme or enzyme inhibitor. The reactive complexes include a substrate joined (e.g., covalently bonded, physically adsorbed, etc.) to a reporter and specific binding member. In one embodiment, for example, a peptide, protein, or glycoprotein substrate is joined to a reporter (e.g., dyed latex particle) and specific binding member (e.g., biotinylated compound). In this embodiment, the substrate provides a cleavage target for a proteolytic enzyme. Specifically, upon contacting the reactive complexes, the proteolytic enzyme cleaves the substrate and releases the reporter and/or specific binding member. The signal exhibited by the released reporters may then be used to indicate the presence or quantity of an enzyme or enzyme inhibitor within the test sample.Type: GrantFiled: February 3, 2011Date of Patent: June 4, 2013Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Xuedong Song
-
Patent number: 8435757Abstract: The activity of a selected endopeptidase in a body fluid is determined by the mass spectrometric measurement of the reaction products of reporter substrate molecules added to the body fluid. Each reporter substrate molecule includes a peptide with the cleavage motif of the endopeptidase, an anchor group A1 on one side of the cleavage site and a different anchor group A2 on the other side of the cleavage site. One anchor is used to extract the reporter substrate molecules from the body fluid and the other anchor is used to extract digest fragments of the reporter molecules from the body fluid. Mass markers allow several reporter substrates to be used simultaneously in the same body fluid sample to measure the activity of different types of endopeptidase.Type: GrantFiled: May 24, 2010Date of Patent: May 7, 2013Assignee: Bruker Daltonik, GmbHInventors: Peter Findeisen, Michael Neumaier
-
Publication number: 20130095515Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.Type: ApplicationFiled: December 10, 2012Publication date: April 18, 2013Applicant: MOMENTA PHARMACEUTICALS, INC.Inventor: Momenta Pharmaceuticals, Inc.
-
Patent number: 8420345Abstract: The present invention relates to a method for identifying at least two groups of microorganisms expressing the same enzymatic activity, comprising the following steps: a) incubating said groups of microorganisms in a reaction medium comprising a first enzyme substrate and a second enzyme substrate, said first and second enzyme substrates being metabolized by the same enzymatic activity; b) identifying said groups of microorganisms.Type: GrantFiled: February 23, 2007Date of Patent: April 16, 2013Assignee: BiomerieuxInventors: Sylvain Orenga, Celine Roger-Dalbert, Arthur James, John Perry
-
Publication number: 20130079425Abstract: Specific peptides are provided that are derived from subsequences of the urokinase-type plasminogen activator protein and the plasminogen activator inhibitor type-1 protein along with assays that can measure those peptides directly in complex protein lysate samples, including protein lysates prepared from histologicaly-processed formalin fixed tissue. The presence and amount of those peptides in samples from a subject can be associated with disease, including cancer, in a subject and provide information about the diagnostic stage/grade/status of the disease/cancer.Type: ApplicationFiled: November 26, 2012Publication date: March 28, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventor: Expression Pathology, Inc.
-
Publication number: 20130078661Abstract: Provided are compositions and methods for Fluorescence/Forster Resonance Energy Transfer (FRET) analysis of cleavage of Von Willebrand Factor (VWF) polypeptides by the metalloprotease ADAMTS13. The polypeptides contain: i) a first fluorescent protein ii) a VWF amino acid sequence and iii) a second fluorescent protein. The VWF amino acid can contain any of a variety of amino acid substitutions. The method involves contacting a sample that contains ADAMTS13 and using FRET based measurements to determine ADAMTS13 cleavage of the recombinant polypeptide.Type: ApplicationFiled: June 6, 2011Publication date: March 28, 2013Applicant: The Research Foundation for The State University of New YorkInventors: Sriram Neelamegham, Kannayakanahalli Dayananda
-
Publication number: 20130078645Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4.Type: ApplicationFiled: January 28, 2011Publication date: March 28, 2013Applicant: PSYNOVA NEUROTECH LTD.Inventors: Sabine Bahn, Marlis Huebner
-
Publication number: 20130052654Abstract: Members of the Amyloid Precursor Protein family (APP molecules) and their neurotoxic cleavage product A? are key players in the development of Alzheimer's disease (AD). Proteolytic processing of APP molecules is influenced by metal ions, protein ligands and its oligomerization state. X-ray structures of the metal bound molecule at 2.6-2.0 ? resolution are presented, providing structural and functional bases for the regulation of APP molecules using conformational information. A metal-dependent molecular switch located within the E2 domain of APP coinciding with a high affinity copper and zinc binding site within the monomeric E2 domain was evaluated. The metal specific coordination spheres of this E2 domain comprise four evolutionary conserved histidine residues. Metal binding induces large conformational changes relative to the metal free protein. This conformational change provides a basis for influencing APP molecule processing and thus trafficking and the production of A?.Type: ApplicationFiled: August 30, 2012Publication date: February 28, 2013Applicant: Leibniz Institute For Age Research - Fritz Lipmann Institute (FLI)Inventors: Sven Dahms, Manuel Than, Dirk Roeser, Ina Koennig
-
Publication number: 20130052642Abstract: Method for the isolation and purification of nTreg cells from a biological sample, preferably from an individual having an inflammatory or autoimmune disease. Furthermore, the invention additionally relates to a kit for the isolation or purification of nTreg cells from a biological sample.Type: ApplicationFiled: January 24, 2011Publication date: February 28, 2013Applicant: Universidade De Santiago De CompostelaInventors: Montserrat Nogueira Álvarez, Francisco Javier Salgado Castro, Pilar Arias Crespo, Amparo Pérez Díaz, Nora Martínez Villanueva
-
Publication number: 20130045498Abstract: The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. 1) equipped with at least one pressure sensor (FIG. 1 (4)) to determine the change in the fluid viscosity over time as a measure of the enzyme activity.Type: ApplicationFiled: March 1, 2011Publication date: February 21, 2013Applicant: NOVOZYMES A/SInventors: Gernot J. Abel, Dan Petterson
-
Patent number: 8361740Abstract: The invention relates to methods for making a peptide standard for mass spectrometry said method comprising (a) identifying endopeptidase cleavage sites in a parent polypeptide sequence of interest; (b) selecting peptide sequences from said parent polypeptide which are defined by endopeptidase cleavage sites of step (a); (c) adding a C-terminal extension to each selected sequence; wherein if the endopeptidase cleavage site is C-terminal to its recognition sequence then the C-terminal extension comprises 1 to 6 amino acids, wherein if the endopeptidase cleavage site is N-terminal to its recognition sequence then the C-terminal extension comprises said recognition sequence, wherein if the endopeptidase cleavage site is within its recognition sequence then the C-terminal extension comprises the remainder of said recognition sequence C-terminal to the cleavage site; and (d) synthesizing a peptide having the extended amino acid sequence of step (c).Type: GrantFiled: May 2, 2008Date of Patent: January 29, 2013Assignees: King's College London, Guy's and St. Thomas' NHS Foundation TrustInventors: Charles Turner, Raymond Neil Dalton
-
Patent number: 8329391Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues.Type: GrantFiled: March 20, 2009Date of Patent: December 11, 2012Assignee: Momenta Pharmaceuticals, Inc.Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern